Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion

Abstract Relapses of CD19-expressing leukemia in patients who achieved initial remission after CART cell treatment have been reported to correlate with poor CART cells persistence. Sustained tonic signaling or strong activation drives CART cell differentiation and exhaustion, which limit the therape...

Full description

Bibliographic Details
Main Authors: Hao Zhang, Yongxian Hu, Mi Shao, Xinyi Teng, Penglei Jiang, Xiujian Wang, Hui Wang, Jiazhen Cui, Jian Yu, Zuyu Liang, Lijuan Ding, Yingli Han, Jieping Wei, Yulin Xu, Xiaoqing Li, Wei Shan, Jimin Shi, Yi Luo, Pengxu Qian, He Huang
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Journal of Hematology & Oncology
Subjects:
Chimeric antigen receptor T cells
Acute lymphoblastic leukemia
Tyrosine kinase inhibitor
Dasatinib
Differentiation
Exhaustion
Online Access:https://doi.org/10.1186/s13045-021-01117-y

Internet

https://doi.org/10.1186/s13045-021-01117-y

Similar Items